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Background Ischaemic heart disease is a leading cause of mortality in women. Even in those without obstructive coronary artery
disease (CAD), women with angina continue to have increased mortality. There are gender differences in preva-
lence of different pathophysiologies, including functional disorders such as microvascular and vasospastic angina.
...................................................................................................................................................................................................
Case summary We describe four cases of angina in women with no obstructive CAD, in whom coronary function testing was per-
formed. These four patients were diagnosed with disorders of coronary vasomotion, including vasospastic angina
and different endotypes of microvascular angina.
...................................................................................................................................................................................................
Discussion This case series highlights the different mechanisms of ischaemia in the absence of obstructive CAD. Patients with
angina and no obstructive CAD classified by computed tomography coronary angiography may have myocardial is-
chaemia due to microvascular angina, vasospastic angina, or both. Conventional investigations risk under-diagnosing,
and as a consequence under-treating, patients with these conditions. Coronary function testing, in the form of diag-
nostic guidewire-based tests and adjunctive acetylcholine provocation, has proven to be critical in the accurate
diagnoses and appropriate management of these patients.
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Introduction
Ischaemic heart disease (IHD) is a leading cause of premature mor-
bidity and mortality.1,2 Although mortality from IHD has fallen in
men, this is less apparent in younger women.3 Sex differences in the
prevalence of distinct pathophysiologies of IHD may be relevant.
Recent IHD guidelines reflect the diverse spectrum and aetiopatho-
genesis of patients with chronic coronary syndromes,4 with new em-
phasis on functional disorders such as microvascular angina and
vasospastic angina. These are more common in women.5 The WISE
Learning points
• Coronary vascular dysfunction (including microvascular angina
and vasospastic angina) may cause ischaemia with no obstruct-
ive coronary artery disease, especially in women.
• An anatomical imaging mode of investigation risks overlooking
coronary vascular dysfunction in patients presenting with
angina.
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study, in particular, showed that one-third of cardiac deaths in their
cohort occurred in women without obstructive coronary artery dis-
ease (CAD).6 Ischaemia with no obstructive CAD is increasingly rec-
ognized as an important entity, and the underlying mechanisms merit
further study.
This report describes four female patients with angina in whom
obstructive CAD was ruled out by computed tomography coronary
angiography (CTCA). Each patient gave informed consent to enrol in
a randomized controlled trial (CorCTCA, ClinicalTrials.gov
NCT03477890) assessing the effect of a clinical strategy of stratified
medicine on diagnosis, treatment, and well-being. They were invited
to undergo invasive coronary angiography (CAG) and adjunctive
tests of coronary vascular function as part of the study protocol. The
latter involved the measurement of coronary flow reserve (CFR) and
index of microvascular resistance (IMR) using a coronary thermodilu-
tion technique with a pressure- and temperature-sensitive diagnostic
coronary guidewire,7 and acetylcholine provocation testing with infu-
sions of incremental acetylcholine concentrations (10-6M, 10-5M,
10-4M), each delivered over 2min. The thermodilution technique
requires 3mL of saline at room temperature to be injected briskly
into the coronary artery to obtain a resting thermodilution curve.
Three resting thermodilution curves are obtained to derive a mean
transit time. This is repeated during hyperaemia, which is induced by
adenosine, to obtain three hyperaemic thermodilution curves.
Coronary flow reserve and IMR can then be calculated. This stratified
medicine protocol5 is supported by contemporary practice
guidelines.4
Timeline
Case presentation
Patient 1
A 46-year-old woman presented to the cardiology clinic with a 6-
year history of chest tightness radiating to her left shoulder,
occurring predominantly on exertion but also at rest. She
reported difficulty climbing stairs due to her symptoms. She had
not been prescribed any cardiac medication and her medical ther-
apy consisted only of duloxetine for depression and pregabalin for
chronic back pain. Her past medical history included emphysema,
depression, osteoarthritis, irritable bowel syndrome with previ-
ous normal gastroscopy and sigmoidoscopy, and previous chole-
cystectomy. She underwent a treadmill exercise tolerance testing
(ETT) but was only able to exercise for 3min and 3 s, stopping
due to leg fatigue. She had no chest pain or changes on her elec-
trocardiogram (ECG). The ETT was deemed inconclusive and she
subsequently had a CTCA which showed normal coronary
arteries. The diagnosis made by her attending cardiologist was
non-cardiac chest pain.
Invasive CAG confirmed the CTCA findings of angiographically
normal coronary arteries. Coronary vascular function testing was
performed in the left anterior descending coronary artery (LAD)
and the IMR (12, normal < 25) and CFR (5.0, normal > 2.0) were
normal. On acetylcholine provocation testing, epicardial vaso-
spasm was observed, accompanied by transient chest pain, but
without ECG changes (Figure 1). The vasospasm and chest pain
resolved with administration of intracoronary glyceryl trinitrate
......................................................................................................................................................................................................................
Patient 1 Patient 2 Patient 3 Patient 4
Time 0—computed tomography coronary angiography (CTCA)
Duration of symptoms 6 years 2 years 2 years 9 months
CTCA findings Normal coronary arteries Normal coronary arteries Non-obstructive coronary ar-
tery disease (CAD)
Plaque in left anterior
descending artery (LAD)
Time 1—invasive coronary angiography (CAG) and coronary function testing
CAG findings Normal coronary arteries Myocardial bridging in mid-
LAD
Non-obstructive CAD Tortuous coronary arteries
Coronary function test Coronary flow reserve (CFR)
5.0
CFR 1.7 CFR 1.5 CFR 1.6
Index of microvascular resist-
ance (IMR) 12
IMR 24 IMR 11 IMR 41
Acetylcholine provocation
test
Epicardial vasospasm with re-
production of chest pain
Microvascular spasm with re-
production of chest pain
and electrocardiogram
(ECG) changes
Reproduction of chest pain
with ECG changes
No response
Randomization group Standard, angiography-guided
arm
Standard, angiography-guided
arm
Standard, angiography-guided
arm
Standard, angiography-guided
arm
Management Likely non-cardiac chest pain;
no changes to medication
Probable non-cardiac chest
pain; no changes to
medication
Possible microvascular angina;
statin therapy started
Possible microvascular angina;
no changes to medication
Time 2—follow-up
Time to follow-up (months) 12 12 12 6
Diagnosis Vasospastic angina Microvascular angina Microvascular angina Microvascular angina
Management Tildiem 200mg Verapamil 240 mg and statin
therapy
Amlodipine and bisoprolol
switched to verapamil
120mg and ramipril 2.5mg
—
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(GTN). These findings were consistent with a diagnosis of vaso-
spastic angina.
The patient had been randomized to the standard, angiography-
guided arm of the trial, and therefore the cardiologist was unaware of
the coronary function findings. A diagnosis of non-cardiac chest pain
was made.
At 12months, she reported persistent chest symptoms. Her
sublingual GTN spray, which had been discontinued by her primary
care physician, was restarted and she was commenced on
diltiazem.
Patient 2
A 42-year-old woman presented with a 2-year history of typical an-
gina following the onset of premature menopause. At the time of
presentation, she described angina consistent with Canadian
Cardiovascular Society (CCS) Class II severity, with predictable chest
tightness when walking up hills. She reported no symptoms at rest.
The patient had been prescribed propranolol 10mg three times daily
for anxiety and an oestrogen patch for hormone replacement ther-
apy. She was an ex-smoker and her past medical history included
obesity, migraine, and depression. She underwent an ETT, exercising
for 6min and 23 s with reproduction of chest pain at 4min but no
ECG changes. The test was stopped due to dyspnoea and fatigue.
Her attending cardiologist felt that CAD could not be excluded and
referred her for a CTCA, which showed normal coronary arteries.
Invasive CAG revealed myocardial bridging in the mid-LAD.
Coronary flow reserve on coronary function testing was low at 1.7,
with a borderline IMR of 24. On acetylcholine provocation testing,
there was a transient reduction in antegrade flow in the LAD without
evidence of epicardial vasospasm (Figure 2). The patient experienced
transient chest pain and the ECG disclosed ST elevation in leads I and
aVL with reciprocal ST depression in leads II, III, and aVF. The angio-
graphic appearance following acetylcholine, accompanied by the re-
production of her usual symptoms and ECG changes, was consistent
with microvascular spasm, an endotype of microvascular angina.
The patient had been randomized to the standard, angiography-
guided arm of the trial. She was diagnosed with probable non-cardiac
chest pain. No changes to her medication were made.
At 12months, the patient was unblinded. Her angina status
remained consistent with CCS Class II severity and she was pre-
scribed verapamil 240mg daily and statin therapy. Her primary care
physician had referred her to the cardiac rehabilitation service for
supervised exercise. Four months later, she reported an improve-
ment in her angina. Her exercise tolerance had improved and she
only had symptoms when the weather was particularly cold. Her
Seattle Angina Questionnaire—Physical Limitation (SAQ-PL)
score had improved from 55 to 72 following the introduction of
verapamil.
Patient 3
A 59-year-old woman presented with a 2-year history of left-sided
chest tightness radiating down her left arm, occurring predominantly
on exertion but also at rest. She reported symptoms on walking up
an incline. She was treated with amlodipine 5mg daily for hyperten-
sion. She also had a history of hyperlipidaemia, previous hysterec-
tomy, fibromyalgia, and sciatica. Following the onset of stable chest
pain, her primary care physician had prescribed bisoprolol 2.5mg
daily, which had slightly improved her symptoms. The CTCA scan
disclosed minor plaque in the right coronary artery (RCA) and a cal-
cified, non-obstructive (<50%) stenosis in the proximal LAD.
Invasive CAG confirmed non-obstructive plaque in the RCA and
proximal to mid-LAD. Fractional flow reserve in the LAD was 0.87
(normal>_ 0.80), confirming non-obstructive CAD. On coronary
function testing, CFR was 1.5 and IMR was 11. Acetylcholine provo-
cation disclosed normal angiographic responses, but the patient
experienced chest pain with anterior ST depression (Figure 3). This
resolved with intracoronary GTN. There was evidence of both
Figure 1 Patient 1—coronary function test results, angiographic
changes on acetylcholine provocation testing and electrocardio-
graphic findings. Coronary vascular function testing was performed
in the LAD using the thermodilution technique with the
CoroventisVR software. Coronary flow reserve and index of micro-
vascular resistance were both normal (A). The LAD was unob-
structed (B), but on acetylcholine provocation testing, there was
epicardial vasospasm from the mid to distal segment (C). The
patient’s electrocardiogram (E) was largely unchanged from baseline
(D).
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reduced coronary vasorelaxation (reduced CFR) and microvascular
spasm (chest pain with ECG changes, despite the absence of change
in coronary flow on angiography), consistent with a diagnosis of
microvascular angina.
The patient had been randomized to the standard,
angiography-guided arm of the trial. Her attending cardiologist
felt that microvascular angina was possible, but did not make any
changes to her antianginal medication. Statin therapy was
prescribed.
At 12months, the patient was unblinded. She reported persistent
angina (CCS Class III). She was given a diagnosis of microvascular
angina and her amlodipine and bisoprolol were changed to verapamil
120mg daily and ramipril 2.5mg daily. Three months later, she
reported an improvement in her symptoms, although she continued
to have CCS Class II angina. Her SAQ-PL score had improved slightly
from 44 to 47.
Figure 3 Patient 3—coronary function test results, angiographic
findings on acetylcholine provocation testing and electrocardio-
graphic changes. Coronary vascular function testing was performed
in the LAD using the thermodilution technique with the
CoroventisVR software. Coronary flow reserve was low at 1.5 (A).
There was mild, non-obstructive disease in the LAD (B). There was
no change in flow or vessel diameter on acetylcholine challenge (C),
however, the patient had chest pain with anterior ST depression
(E), which was not present at baseline (D).
Figure 2 Patient 2—coronary function test results, angiographic
changes on acetylcholine provocation testing and electrocardio-
graphic changes. Coronary vascular function testing was performed
in the LAD using the thermodilution technique with the
CoroventisVR software. Coronary flow reserve was low at 1.7 (A).
The LADwas unobstructed (B). On acetylcholine provocation test-
ing, there was a loss of flow in the LAD (C), accompanied by high lat-
eral ST elevation and inferior ST depression (E), which were not
present at baseline (D).
4 N.P. Sidik et al.
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Patient 4
A 51-year-old woman presented with a 9-month history of atypical
chest pain. She reported predominantly exertional, but also
non-exertional left-sided chest pain radiating to her jaw. Her symp-
toms would occur on walking up an incline. She had not been pre-
scribed any cardiac medication. She underwent an ETT and
developed chest pain at 1min and 23 s which worsened with contin-
ued exercise. The test was stopped at 6min and 22 s due to limiting
chest pain. There were no ECG changes. A subsequent CTCA scan
revealed plaque in the proximal LAD.
Invasive CAG revealed tortuous coronary arteries with no ob-
structive disease. On coronary function testing, CFR was 1.6 and IMR
was 41 (Figure 4). These findings reflected reduced coronary vasore-
laxation and increased microvascular resistance, which were consist-
ent with a diagnosis of microvascular angina. Coronary reactivity
testing with acetylcholine was negative.
The patient was randomized to the standard, angiography-guided
arm of the trial. The cardiologist was blinded to the results of the cor-
onary vascular function test, and the decision to prescribe antianginal
therapy was left to her primary care physician.
At 6months, the patient reported worsening anginal symptoms
and lethargy. She had not been prescribed any antianginal therapy.
Blinded follow-up is ongoing.
Discussion
A clinical strategy of anatomical imaging of the coronary arteries,
which is currently recommended as the first-line test in UK practice
guidelines,8,9 does not take into account the disorders of coronary
vasomotion and related susceptibility to myocardial ischaemia.
Patients with angina and no obstructive CAD classified by CTCA
may have myocardial ischaemia due to microvascular angina,
vasospastic angina, or both. Conventional investigations risk
under-diagnosing, and as a consequence under-treating, patients with
these conditions. Quality of life, anginal symptoms, and prognosis
may be persistently impaired when the management of these patients
is guided solely by an anatomical strategy.5
In contrast, the practice guidelines of the European Society of
Cardiology now recommend assessing coronary vascular function in
patients with angina and no obstructive CAD.4 Stratified medicine
promotes patient-centred care and is prognostically informative.10
Distinguishing the different endotypes of coronary vascular dysfunc-
tion (e.g. microvascular spasm vs. high microvascular resistance) leads
to personalized therapy, which in turn leads to improved symptoms.5
First-line therapy for patients with microvascular angina consists of a
beta-blocker, unless they have predominantly microvascular spasm,
which should be treated like vasospastic angina with a calcium chan-
nel blocker. Add-on therapy includes calcium channel blockers and
nicorandil in microvascular angina and a long-acting nitrate in vaso-
spastic angina.
This case series highlights the different mechanisms of ischaemia in
the absence of obstructive CAD. Coronary function testing, in the
form of diagnostic guidewire-based tests and adjunctive acetylcholine
provocation, has proven to be critical in the accurate diagnoses and
appropriate management of these patients. The CorCTCA study will
determine the prevalence of these conditions in a comparatively
unselected patient population and whether stratified medicine will
benefit these patients.
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